Dr. Lal PathLabs Ltd (NSE: LALPATHLAB): Dr Lal PathLab is a pathology laboratory company that has released its quarterly results. In its stock exchange filing, Dr Lal PathLab reported that profits and earnings had both increased.
The company’s consolidated profit has increased from Rs 53 crore to Rs 81 crore.
The consolidated earnings have also increased. The consolidated earnings of the company have increased from Rs 489 crores to Rs 539 crores.
EBITDA has also increased. EBITDA grew from Rs 113 crore to Rs 141 crore. Profit margins have also increased. The margin increased from 23.1 percent to 26.1 percent.
All these figures have been released by the company on an annual basis.
The company also announced dividends for investors. The company has announced an interim dividend of Rs 12 per share.
The biggest dividend has been given by Dr. Lal Path Lab. The company announced a dividend of 120 percent on Rs 10 face value.
The company had previously declared dividends of Rs 6 in August 2023, Rs 5 in August 2022, and Rs 6 in June 2022.
Since 2016, the company has declared dividends to investors. The record date for this dividend is 13 February 2024.
The share will reach at the price of Rs 3000.
About Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Limited is one of the most reputable companies in India.
The Company’s business includes biochemistry, histopathology, hematology, microbiology, immuno-chemistry, electrophoresis, immunology, cytology, virology, and other radiological and pathological investigations.
Paliwal Medicare Private Limited, one of its subsidiaries, is a company that provides healthcare services.
Paliwal Diagnostics Private Limited and Dr. Lal PathLabs Nepal Private Limited are also part of the company.
The company provides tests for allergies, health checks, diabetes, viral infection, fever, hypertension and heart disease, cancer, and anemia.
The company’s total operating revenue is Rs 1769.03 crores. Its equity capital is at Rs 83.37 Crores.
The company was founded on 4th February 1995. Delhi, India is its main office.
Fundamental Analysis of Dr. Lal PathLabs Ltd
| Market Cap | ₹ 20,915 Cr. |
| Current Price | ₹ 2,513 |
| 52-wk High | ₹ 2,767.10 |
| 52-wk Low | ₹ 1,762.05 |
| Stock P/E | 69.39 |
| Book Value | ₹ 212 |
| Dividend | 0.48 % |
| ROCE | 18.2 % |
| ROE | 15.0 % |
| Face Value | ₹ 10.0 |
| P/B Value | 11.8 |
| OPM | 26.7 % |
| EPS | ₹ 39.5 |
| Debt | ₹ 299 Cr. |
| Debt to Equity | 0.17 |
Dr. Lal PathLabs Share Price Target 2024 To 2030
| Year | 1st Target | 2nd Target |
| 2024 | ₹2598 | ₹2900 |
| 2025 | ₹3100 | ₹3200 |
| 2026 | ₹3345 | ₹3542 |
| 2027 | ₹3600 | ₹3680 |
| 2028 | ₹3700 | ₹3748 |
| 2029 | ₹3800 | ₹3984 |
| 2030 | ₹4100 | ₹4200 |
Dr. Lal PathLabs Ltd Shareholding Pattern
| Promoters Holding | |
| Dec 2022 | 55.04% |
| Mar 2023 | 55.03% |
| June 2023 | 55.01% |
| Sept 2023 | 54.61% |
| Dec 2023 | 54.60% |
| FII Holding | |
| Dec 2022 | 25.80% |
| Mar 2023 | 24.89% |
| June 2023 | 23.27% |
| Sept 2023 | 24.35% |
| Dec 2023 | 25.36% |
| DII Holding | |
| Dec 2022 | 6.20% |
| Mar 2023 | 6.56% |
| June 2023 | 8.34% |
| Sept 2023 | 8.85% |
| Dec 2023 | 9.27% |
| Govt. Holding | |
| Dec 2022 | 0.00% |
| Mar 2023 | 0.00% |
| June 2023 | 0.29% |
| Sept 2023 | 0.29% |
| Dec 2023 | 0.29% |
| Public Holding | |
| Dec 2022 | 12.38% |
| Mar 2023 | 13.01% |
| June 2023 | 12.65% |
| Sept 2023 | 11.48% |
| Dec 2023 | 10.12% |
| Others Holding | |
| Dec 2022 | 0.56% |
| Mar 2023 | 0.51% |
| June 2023 | 0.44% |
| Sept 2023 | 0.41% |
| Dec 2023 | 0.37% |
Dr. Lal PathLabs Ltd Share: Last 5 Years’ Financial Condition.
To gain a better understanding of how the market is performing, let’s look at the outlook of this share in the previous years.
However, investors should be aware of the risks and the market conditions before making any investment decision.
Last 5 Years’ Sales:
| 2019 | ₹ 1,203 Cr |
| 2020 | ₹ 1,330 Cr |
| 2021 | ₹ 1,581 Cr |
| 2022 | ₹ 2,087 Cr |
| 2023 | ₹ 2,172 Cr |
Last 5 Years’ Net Profit:
| 2019 | ₹ 200 Cr |
| 2020 | ₹ 228 Cr |
| 2021 | ₹ 296 Cr |
| 2022 | ₹ 350 Cr |
| 2023 | ₹ 333 Cr |
Last 5 Years’ Debt-To-Equity Ratio:
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 0 |
| 2022 | 0.23 |
| 2023 | 0.14 |
Last 10 Years’ Profit Growth:
| 10 Years: | 16% |
| 5 Years: | 7% |
| 3 Years: | 2% |
| Current Year: | 35% |
Last 10 years’ Return on Equity (ROE):
| 10 Years: | 24% |
| 5 Years: | 22% |
| 3 Years: | 21% |
| Last Year: | 15% |
Sales Growth Over 10 Years:
| 10 Years: | 16% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| Current Year: | 8% |
Conclusion
This article is a complete guide about Dr. Lal PathLabs Ltd Share.
These information and forecasts are based on our analysis, research, company fundamentals and history, experiences, and various technical analyses.
Also, We have talked in detail about the share’s future prospects and growth potential.
Hopefully, these informations will help you in your further investment.
If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.
